About CKD bio
CKD bio is a publicly listed company based in Seoul (South Korea) founded in 1941. APIs and intermediates are manufactured with fermentation specialization. The company has 509 employees. CKD bio offers products and services including Pharmaceutical Drugs and Health Functional Foods. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is Chong Kun Dang Holdings Corp.
Company details
CKD Bio was founded in 1941 in Seoul, South Korea, and operates in the pharmaceutical sector. APIs and intermediates are developed and manufactured, focusing on fermentation-based processes for categories such as antibiotics, beta-lactamase inhibitors, antidiabetics, immunosuppressants, antihyperlipidemics, and probiotics. Contract research and manufacturing services are provided. Eight products are under development for various indications.
- Headquarters Seoul, South Korea
- Employees 509
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ckdbio.com
- Social LinkedIn X
- Legal Name Ckd Bio Corp.
- Annual Revenue$110.84 M (USD)-6.8as on Dec 31, 2025
- Net Profit-$2 M (USD)-133.2as on Dec 31, 2025
- EBITDA$13.29 M (USD)-30.53as on Dec 31, 2025
- Employee Count509
Products & Services of CKD bio
CKD bio offers a comprehensive portfolio of products and services, including Pharmaceutical Drugs and Health Functional Foods.
Manufactures drugs for health treatment and disease management
Provides nutritional products to support consumer health promotion
People of CKD bio
1 people are tracked at CKD bio (1 in leadership); the tracked headcount is 509.
| Name | Role | Group |
|---|---|---|
Jeong-jin Lee | CEO | Leadership |
Complete people profiles for CKD bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CKD bio
CKD bio is a publicly listed company on the KRX with ticker symbol 063160 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Dec 2001
- Listed onKRX: 063160
- Listed entityCKD Bio Corp.
- Exchange sectorHealth technology
- ISINKR7063160006
- Share price13,120.00 KRW (-2.53% on the day) · 2026-10-14
- Market capitalisation73,841,008,854.00 KRW
- EPS (diluted, trailing year)-1,958.22 KRW
- Volume (last session)13,310
Financials of CKD bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 160.07B KRW | -2.89B KRW | 19.20B KRW |
| 2024 | 171.76B KRW | 8.70B KRW | 27.64B KRW |
| 2023 | 160.35B KRW | -24.19B KRW | -2.61B KRW |
| 2022 | 156.04B KRW | -16.70B KRW | 3.09B KRW |
| 2021 | 142.24B KRW | -6.58B KRW | 5.25B KRW |
Detailed financial statements for CKD bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of CKD bio
The website of CKD bio (ckdbio.com) receives about 4.6K visits a month and ranks #3,295,379 among all websites worldwide, #4,343 in Biotechnology and Pharmaceuticals.
- Monthly visits4.6K
▼ 30.7% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,295,379
among all websites
- Category rank#4,343
Health · Biotechnology and Pharmaceuticals
- Bounce rate61%
- Pages per visit1.4
- Average visit16 sec
- DevicesDesktop 19% · Mobile 81%
Websites whose visitors overlap most with CKD bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kolonls.co.kr | 100% | 4.6K | #2,572,555 | View details | |
tacanow.org | tacanow.org | 60% | #640,240 | – | |
| whanin.com | 60% | 74.9K | View details | ||
bellins.net | bellins.net | 30% | #4,661,076 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ckd Bio
Complete news archive for CKD bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CKD bio
CKD bio was founded in 1941.
CKD bio is headquartered in Seoul, South Korea.
CKD bio has 509 employees.
Annual revenue of CKD bio is $110.84M as on Dec 31, 2025.
CKD Bio was founded in 1941 in Seoul, South Korea, and operates in the pharmaceutical sector. APIs and intermediates are developed and manufactured, focusing on fermentation-based processes for categories such as antibiotics, beta-lactamase inhibitors, antidiabetics, immunosuppressants, antihyperlipidemics, and probiotics. Contract research and manufacturing services are provided. Eight products are under development for various indications.
CKD bio offers Pharmaceutical Drugs and Health Functional Foods.
Yes, CKD bio is publicly traded on KRX under the ticker symbol 063160.
CKD bio operates through Chong Kun Dang Holdings Corp..